ADMA Biologics, Inc. (NASDAQ:ADMA) has seen a significant sale of its stock by Director Steve Elms, according to a recent SEC filing. Elms, who is associated with Aisling Capital II LP, disposed of a total of 460,716 shares of the company's common stock over two separate transactions on March 18 and March 19, 2024. The total value of the shares sold amounts to $2,803,741, with the price per share ranging from $6.01 to $6.08.
The first sale on March 18 involved 49,887 shares at a weighted average price of $6.01, with the sales prices varying between $6.00 and $6.02. The following day, Elms sold 411,829 shares at an average price of $6.08, with individual sales prices ranging from $6.00 to $6.17. Post these transactions, Elms indirectly retains a substantial holding of 2,115,671 shares in the company.
The shares are indirectly owned through Aisling Capital II LP, where Elms serves as a Managing Member of Aisling Capital Partners, LLC, which is a control person of Aisling, and also as a member of the investment committee of Aisling Capital Partners, LP. While Elms may be deemed to be the beneficial owner of these shares, he has disclaimed beneficial ownership except to the extent of his pecuniary interest.
Additionally, the SEC filing includes a footnote indicating that Elms also has direct ownership of 76,441 shares, which comprises 24,040 restricted stock units set to vest on future anniversaries of the grant date, and 52,401 shares of common stock.
Investors and followers of ADMA Biologics will be keeping a close watch on these transactions as they reflect significant insider activity within the company. The biopharmaceutical company, which specializes in the development and commercialization of immune globulin products, has not provided any specific reason for the sale by Elms.
ADMA Biologics' stock performance and insider transactions such as these are often closely monitored by investors seeking insights into company health and executive confidence.
InvestingPro Insights
Amidst the insider selling activity at ADMA Biologics, Inc. (NASDAQ:ADMA), investors may find the broader financial landscape of the company to be of interest. According to InvestingPro, ADMA has experienced a remarkable revenue growth of 67.59% over the last twelve months as of Q4 2023. This growth is further highlighted by an impressive quarterly revenue growth of 47.86% in Q1 2023, signaling a strong upward trajectory for the company's sales.
The company's market capitalization stands at $1.41 billion, reflecting its scale in the biopharmaceutical industry. However, ADMA's Price to Earnings (P/E) ratio is currently negative at -48.34, indicating that the company has not been profitable over the last twelve months. This is further emphasized by a high Price to Book (P/B) ratio of 10.45, suggesting that the stock is trading at a premium relative to the company's book value.
Despite the negative P/E ratio, ADMA is forecasted to see net income growth this year, as per InvestingPro Tips. This could be a pivotal factor for potential investors, as profitability prospects often influence investment decisions. Additionally, ADMA has been trading near its 52-week high with a price percentage of 96.49%, demonstrating strong market confidence and a significant price uptick over the last six months.
For those interested in further analysis and additional InvestingPro Tips, there are 13 more tips available on InvestingPro, providing deeper insights into ADMA's financial health and market performance. Readers can also take advantage of an exclusive offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of investment knowledge and data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.